JNPMEDI
JNPMEDI is a life sciences RDC (Research, Development, and Commercialization) company that provides end-to-end solutions built around its proprietary Maven Clinical Cloud platform to accelerate the clinical journey of pharmaceutical, biotech, and medical device clients.
# Digital Healthcare # Maven Clinical Cloud # Clinical Data Solution # AI #DCT #FDA #MFDS #CRO #RA consulting
Company Info.
Contact Info.
Kwunho Jeong I CEO
31F, Posco Tower, 165, Convensia-daero, Yeonsu-gu, Incheon, 21998
+82-1668-0774
JNPMEDI Sales
1668-0774
Company Info.
Bongho Lee ㅣ CEO
INSTAR2, 204 Convensia-daero, Yeonsu-gu, Incheon, 22004
+82-1855-1317
Contact Info.
Bongho Lee ㅣ CEO
+82-10-9669-2053
Company Profile
JNPMEDI is a dedicated life sciences RDC (Research, Development, and Commercialization) firm providing comprehensive, end-to-end eClinical solutions.
We leverage our proprietary platform, Maven Clinical Cloud®, to streamline and accelerate the entire clinical journey, from strategy and product development to regulatory approval and licensing-out. Our mission is to empower pharmaceutical, biotech, and medical device clients with agile, data-driven tools for efficient research and rapid market entry.
Company Competitiveness
Integrated End-to-End Platform
Unlike fragmented solutions, Maven Clinical Cloud integrates all aspects of the clinical journey—from strategy and R&D to regulatory approval and commercialization—into a single, cohesive platform. This unifies data and workflows, significantly reducing operational friction and the risk of errors.
Accelerated RDC Process
By streamlining complex clinical trials and regulatory processes, the platform ensures faster data acquisition and management, enabling pharmaceutical, biotech, and medical device companies to achieve more rapid market entry for their products. ·
Data-Driven Agility
The platform leverages advanced data analytics for agile decision-making throughout the clinical trial process, enabling real-time monitoring and adaptive strategies that are essential for modern clinical research efficiency.
Focus on Client Success
JNPMEDI positions itself as a partner, providing on-demand solutions and expertise that empower clients to navigate the regulatory landscape and achieve their RDC goals efficiently.
Key Product
Maven CDMS (Clinical Data Management System)
Maven CDMS is an end-to-end platform designed for comprehensive clinical trial data management. It ensures data integrity and compliance by securely collecting, cleaning, and managing Electronic Case Report Forms (eCRFs). This robust and user-friendly system significantly accelerates the data management lifecycle and provides essential oversight of data to advance clinical development and ensure regulatory submission readiness.
Maven eCOA (Electronic Clinical Outcome Assessment)
Maven eCOA captures patient-reported outcomes (ePRO) and clinical observations (eObs) directly from participants using various devices. It enhances data quality and reduces transcription errors by collecting real-time source data at the point of care. The platform is key to improving patient engagement and adherence and to supporting complex trial designs. It ensures regulatory compliance for both subjective and objective data, generating high-quality clinical evidence.
Consulting Service
The MT&G Offering Group builds market entry strategies tailored to each product, combining regulatory approval with reimbursement and coverage planning for true end-to-end market access.
① Dedicated teams and experts to navigate complex domestic and global market access, including regulatory approval and reimbursement
② Full lifecycle support from early market access strategy through to execution
③ Project teams built on proven expertise in RA, reimbursement, ICC, and clinical trials
Company History
2025
-
Launched ‘Maven TMF’&’Converter’, Secured strategic investment from NAVER and TBT
2024
-
Established JNPMEDI Partners, Launched AI-powered ‘Maven Coder Express’ and ‘Maven VDR’
2023
-
Became CDISC Platinum member, Completed Korea’s first DCT, Launched ‘Maven eRecruitment’
2022
-
Received WHO Drug B3/C3 approval, Secured $14M in Series A funding
2021
-
Launched ‘Maven CDMS’(Clinical data management solution), Secured seed investment
2020
-
Founded